Transfer factor (TF) treatment of patients with HBs-Ag-positive chronic active hepatitis. A prospective, controlled study (author's transl)

• Published in: Klinische Wochenschrift 1979-09, Vol.57 (17), p.893-903
• Main Authors: Sodomann, C P, Maerker-Alzer, G, Havemann, K, Dienst, C, Schultz, H, Mitrenga, D, Schumacher, K, Martini, G A
• Format: Article
• Language: eng ; ger
• Subjects: Adult; Aged; Clinical Trials as Topic; Female; Hepatitis B - drug therapy; Hepatitis B Surface Antigens - analysis; Humans; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Random Allocation; Transfer Factor - therapeutic use; Tuberculin Test
• ISSN: 0023-2173; 1432-1440
• DOI: 10.1007/BF01477028

It is a clinically and experimentally well supported working hypothesis that infection with hepatitis B virus may result in chronic active hepatitis in patients with suspected immune deficiencies. On this basis, a pilot study was performed in order to evaluate the effect of "specific" transfer factor (TF) in the treatment of HBS-Ag-positive chronic active hepatitis. From the leukocytes of 500 ml venous blood each of 40 volunteers that had completely recovered from acute virus hepatitis B within the last 6 months, a unique TF pool (40 units of TF) was prepared according to the method of Lawrence. Preexaminations indicated that this preparation was able to enhance cellular immune reactions in vitro. Thirteen patients with HBS-antigenemia and chronic active hepatitis (i.e., two liver biopsies within the last 6 or more months with the histological criteria of chronic aggressive hepatitis according to de Groote, elevated serum levels of bilirubin, alkaline phosphatase, transaminase activities, and/or gamma-globulines) were randomized: Seven received s.c. injections of two units of TF each on days 1 and 15, the other six saline. Conversion of skin reactions to some ubiquitous antigens occurred in the TF group, but no significant and constant drop of HBS-Ag serum titers was observed. Although some of the biochemical parameters seemed to ameliorate in the TF group, the differences versus the control group did not prove to be significant within the limited number of patients under observation. The in vitro reactivity of patients' lymphocytes to HBS-Ag, tested by means of the 3H-thymidine uptake, was never found enhanced after TF application. In the used doses, "specific" TF was not effective in the treatment of HBS-Ag-positive chronic active hepatitis; unfavorable side-effects were not observed.